<DOC>
	<DOCNO>NCT02626793</DOCNO>
	<brief_summary>The objective Non-interventional study ( NIS ) collection data utilization Apremilast routine condition Germany . Patients ' quality-of-life treatment satisfaction treatment Apremilast daily practice document . Moreover , physician 's patient 's assessment effectiveness safety Apremilast record .</brief_summary>
	<brief_title>A Study Otezla® Patients With Plaque Psoriasis Under Routine Conditions</brief_title>
	<detailed_description>The objective NIS ( accord section 67 ( 6 ) German Medicinal Products Act ) documentation data effectiveness tolerability Apremilast treatment routine clinical condition German patient plaque psoriasis . This NIS intend reflect apremilast treatment patient plaque psoriasis receive least one prior conventional , systemic therapy , contraindication present , receive systemic therapy far , diagnose treat physician eligible apremilast treatment . The treatment Apremilast document period approximately 52 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>The decision therapy Apremilast make enrolment independent study . Patient ≥ 18 year age Diagnosis moderate severe plaque psoriasis Inadequate response intolerance previous systemic treatment , contraindication systemic therapy . Written informed consent patient data recording , statistical analysis , file forward data Pregnancy Hypersensitivity apremilast excipients filmcoated tablet Other criterion accord Summary product characteristic ( SmPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Apremilast</keyword>
	<keyword>Otezla®</keyword>
	<keyword>LAPIS-Pso</keyword>
	<keyword>Observational</keyword>
	<keyword>CC-10004</keyword>
	<keyword>non-interventional</keyword>
	<keyword>Germany</keyword>
</DOC>